Whereas impairments in LTM might be a manifestation of prodromal stages of AD, the superior STM performance could instead reflect either phenotypical effects of the APOE gene or compensatory mechanisms that arise due to AD--related or non-AD-related pathology linked to APOE (Bondi et al., 2008, Han et al., 2007, Scheller et al., 2017). The gene discussed is APOE; the disease is Alzheimer disease.